C12N 2760/16062
By genetic engineering
Official title: by genetic engineering
C12N2760/16062 (By genetic engineering) appears on 9 US grants and 13 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 13
- Assignees
- 8
- Inventors
- 27
- Latest grant
- 28 Oct 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 1 | 1 |
| 2019 | 0 | 1 |
| 2020 | 2 | 1 |
| 2021 | 0 | 1 |
| 2022 | 1 | 2 |
| 2023 | 0 | 0 |
| 2024 | 1 | 1 |
| 2025 | 2 | 0 |
By publication year.
Recent patents
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof28 Oct 2025US 12,454,555 B2Sanofi Pasteur Limited
- Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (EIV) in horses8 Jul 2025US 12,350,328 B2University of Kentucky Research Foundation
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof16 Jul 2024US 12,037,364 B2Sanofi Pasteur Limited
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof10 May 2022US 11,325,947 B2Sanofi Pasteur Limited
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof24 Nov 2020US 10,844,097 B2Sanofi Pasteur Limited
- Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same22 Aug 2024US 2024/0277828 A1Sanofi Pasteur Limited
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof4 Aug 2022US 2022/0242918 A1Sanofi Pasteur Limited
- Multivalent Live-attenuated Influenza Vaccine for Prevention and Control of Equine Influenza Virus (EIV) in Horses5 May 2022US 2022/0133877 A1University of Kentucky Research Foundation
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof20 May 2021US 2021/0147488 A1Sanofi Pasteur Limited
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof16 Jul 2020US 2020/0223892 A1Sanofi Pasteur Limited
Most cited
By later US patents
- Viruses encoding mutant membrane protein33US 7,588,769 B2Wisconsin Alumni Research Foundation · 2009
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof2US 10,584,148 B2Sanofi Pasteur Limited · 2020
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof2US 10,844,097 B2Sanofi Pasteur Limited · 2020
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof2US 11,325,947 B2Sanofi Pasteur Limited · 2022